- Details
- In this conversation, Neeraj Agarwal joins Petros Grivas to discuss the Patient-Reported Outcomes (PRO) data from the TITAN study, Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. This data was presented at ESMO 2019. The Food and Drug Administration approved apalutamide (ERLEADA, Janssen Biotech, Inc) for patients with metastatic hormone-sensitive prostate cancer. (mHSPC) in Sept...
|
- Details
- (Length of Interview: 14 min) John Fortin interviews Art Rastinehad on a new publication published in the Proceedings of the National Academy of Science on prostate cancer and nanomedicine. Art Rastinehad and colleagues at Icahn Scool of Medicine at Mount Sinai are the first to perform human trials using nanoshell directed photothermal ablation. In this podcast interview, Dr. Rastinehad reports th...
|
- Details
- Carmel Pezaro discusses her recent move from Australia to Sheffield, England with Alicia Morgans in which they discuss the similarities in the needs of men with prostate cancer in the two countries where men need treatments, support from their families, and their providers. There are differences where in Australia they embrace new technologies such as PSMA PET which is not available in the UK. The...
|
- Details
- Art Rastinehad provides insight into the role of focal therapy in the treatment of prostate cancer. He begins the presentation with the evolution of prostate cancer care. He describes focal therapy in the context of the next significant opportunity in the treatment of prostate cancer once we have a positive biopsy and walks us through the why, the who the how and the where in defining focal therap...
|
- Details
- Alicia Morgans and Adam Kibel discuss the evolving landscape of urologic oncology, specifically focusing on prostate cancer. Dr. Kibel expresses his interest in using genetics, such as single nucleotide polymorphisms, for early identification of high-risk patients and predicting the risk of aggressive prostate cancer. This approach may influence future screening strategies and prophylactic interve...
|
- Details
- Simpa Salami, MD discusses the role of MRI in risk stratifying patients with prostate cancer. MRI has revolutionized the ability to detect aggressive prostate cancer but it is still possible that patients who have a negative MRI still have aggressive cancer. Up to 10-15% of patients may have aggressive prostate cancer despite negative findings on MRI. Dr. Salami addresses why these patients may ha...
|
- Details
- Matthew Cooperberg discusses active surveillance as the standard of care for men with low-risk prostate cancer as well as data from multiple registries including CaPSURE, MUSIC, AQUA, and SEER, which report increasing rates of active surveillance in men with low-risk disease. He further discusses the factors that may be driving lower uptake of active surveillance in some practices. Biographies: Ma...
|
- Details
- Alicia Morgans and Matt Cooperberg discuss the current state of contemporary active surveillance and efforts to standardize strategies nationwide. This conversation also includes discussion on informed decision making and practice patterns of active surveillance and how to tailor based on biology and genetics Biographies: Matthew Cooperberg, MD, MPH, FACS, Associate Professor, Department of Urolog...
|
- Details
- In this interview, Laurence Klotz discusses patients who have yet to be treated but have been diagnosed or in the process of being diagnosed with prostate cancer. Dr. Klotz reviews different case studies including treating a patient with mild elevation of PSA, age-adjusted norms, the use of a risk nomogram in determining significant cancer and deciding on a path of active surveillance. They also d...
|
- Details
- The 68Ga-PSMA PET/CT has a high clinical impact for preoperative staging, restaging biochemical recurrence after radical prostatectomy, and treatment monitoring. Dr. Chen highlights the details of this trial with two objectives. They assessed 68 Ga-PSMA PET/CT in primary prostate cancer with different clinical risks and further studied the inclusion of 11 C-Acetate PET/CT to see if there was an in...
|
